Trial Eligibility
Have you or someone you know been diagnosed with heart failure with preserved ejection fraction (HFpEF)?
AMBER-HFpEF
AMBER-HFpEF is currently recruiting participants to evaluate the safety and efficacy of an investigational drug for heart failure with preserved ejection fraction (HFpEF).
AMBER-HFpEF is a phase 2 placebo-controlled clinical trial researching the investigational drug CK-4021586.
Who
People diagnosed with HFpEF.
Where
Site locations are within the United States; this website is limited to providing information related to sites in this country. For more information, please visit https://clinicaltrials.gov/study/NCT06793371
Travel Expenses
Volunteers who qualify to take part in the study may receive compensation for study-related travel expenses.
CK-4021586 is an investigational drug and is not currently approved for use by regulatory agencies like the FDA – its safety and effectiveness have not been established.